亚太干细胞疗法市场至2018年发展预测报告.pdfVIP

北京佐思信息咨询有限责任公司 Beijing OKOKOK Information Consulting Co.,Ltd 亚太干细胞疗法市场至 2018 年发展预测报告——Stem Cell Therapy Market in Asia-Pacific to 2018 Number of pages: 112 2012-12-14 Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity Summary GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity”. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research‟s team of industry experts. GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals‟ JR-031 (2014) in Japan and FCB Pharmicell‟s Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospital